Creso Pharma receives approval for cannabis acquisition
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Creso Pharma Limited (ASX:CPH) has today announced that regulatory approval from ASX for the shareholder meeting document to approve the transaction with Kunna Canada Ltd has now been received.
Enclosed is a Notice of Meeting for a shareholders’ meeting to be held on 16 October 2018 at 10:00am (WST). Subject to the receipt of shareholder approval, the company anticipates completing the Kunna acquisition in mid-October 2018 and thereafter immediately advancing its business plan in Colombia.
Since first executing the agreement relating to the Kunna acquisition, Colombia has cemented its place as the international jurisdiction of choice for low cost, high quality cannabis production. There have been multiple international (mainly Canadian) companies that have announced transactions to enter Colombia, including from the world’s largest cannabis company Canopy Growth Corp in a transaction worth up to US$96 million.
The company believes these transactions vindicate CPH’s move into Colombia and should provide investors with additional comfort in relation to CPH’s strategy.
Retraction regarding Quarterly Activities Report
CPH notes that, on 31 July 2018, the company’s Quarterly Activities Report stated that the company had completed the Kunna acquisition.
The company intended for this to disclose that due diligence had been completed in relation to the Kunna acquisition. Completion has not occurred, and these statements are hereby retracted by CPH. As noted above, completion is now anticipated to occur in mid-October 2018 (subject to the receipt of shareholder approval).
Once its acquisition of Kunna is finalised, CPH will be one of only a few companies in the world — and the only medicinal cannabis company listed on the ASX — with the capacity to commercially cultivate medicinal-grade cannabis in Colombia.
In June, the company announced that Kunna S.A.S, the wholly owned Colombian subsidiary of Kunna Canada Ltd, had been granted a licence to cultivate medicinal cannabis in the country.
However, it is an early stage of this company’s development in these countries and if considering this stock for your portfolio, you should take all public information into account and seek professional financial advice.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.
